TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Bought by Raymond James & Associates

Raymond James & Associates increased its position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 35.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 170,160 shares of the biopharmaceutical company's stock after acquiring an additional 44,972 shares during the quarter. Raymond James & Associates owned about 0.11% of TG Therapeutics worth $3,980,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of TGTX. NBC Securities Inc. lifted its holdings in shares of TG Therapeutics by 58.9% during the 3rd quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company's stock valued at $30,000 after purchasing an additional 485 shares during the last quarter. Ashton Thomas Private Wealth LLC acquired a new stake in TG Therapeutics in the second quarter worth about $35,000. Blue Trust Inc. grew its stake in shares of TG Therapeutics by 127.3% during the third quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company's stock worth $35,000 after acquiring an additional 849 shares during the last quarter. ORG Wealth Partners LLC acquired a new position in shares of TG Therapeutics during the third quarter valued at about $53,000. Finally, DekaBank Deutsche Girozentrale purchased a new position in shares of TG Therapeutics in the 1st quarter valued at approximately $58,000. Hedge funds and other institutional investors own 58.58% of the company's stock.

Analyst Ratings Changes

Several research firms have weighed in on TGTX. The Goldman Sachs Group boosted their target price on shares of TG Therapeutics from $18.00 to $20.00 and gave the stock a "neutral" rating in a research report on Wednesday, August 7th. TD Cowen started coverage on TG Therapeutics in a research report on Tuesday, October 29th. They issued a "buy" rating and a $50.00 target price on the stock. HC Wainwright reaffirmed a "buy" rating and set a $49.00 price target on shares of TG Therapeutics in a research report on Wednesday, September 18th. Finally, B. Riley increased their price objective on TG Therapeutics from $29.00 to $34.00 and gave the company a "buy" rating in a report on Wednesday, August 7th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $36.33.

TG Therapeutics Stock Performance

TGTX traded down $2.54 during midday trading on Monday, hitting $24.36. 9,595,612 shares of the company were exchanged, compared to its average volume of 3,647,194. The company's 50 day simple moving average is $23.51 and its 200 day simple moving average is $20.10. The firm has a market capitalization of $3.77 billion, a price-to-earnings ratio of 39.62 and a beta of 2.19. TG Therapeutics, Inc. has a 1-year low of $9.81 and a 1-year high of $26.99. The company has a current ratio of 3.58, a quick ratio of 2.83 and a debt-to-equity ratio of 0.58.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last announced its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.04 earnings per share for the quarter, beating the consensus estimate of ($0.04) by $0.08. The company had revenue of $73.47 million during the quarter, compared to analysts' expectations of $65.92 million. TG Therapeutics had a return on equity of 57.73% and a net margin of 27.60%. TG Therapeutics's quarterly revenue was up 357.0% on a year-over-year basis. During the same period last year, the business earned ($0.34) earnings per share. As a group, sell-side analysts predict that TG Therapeutics, Inc. will post 0.13 earnings per share for the current year.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.